News | August 13, 2021
Kovai Medical Center & Hospital PAT at Rs 35.22 cr. for Q1FY22
EPS at Rs 32.19
EPS at Rs 32.19
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The company has predominantly built a portfolio into veterinary products
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
The company also plans to register the similar range of products in the neighbouring countries.
The company is expecting tremendous growth and a better quarterly performance
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
Subscribe To Our Newsletter & Stay Updated
